X4 Pharmaceuticals Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Marc Frahm - Cowen - Analyst : And just to start off with the CN update. And Paula, you laid out there a couple different subtypes. Can you maybe describe the types of patients you've been able to enroll so far? And therefore kind of across those different subtypes, which ones might you be able to update us on in Q3 both from a clinical perspective, but then, at least as importantly, from a regulatory perspective.

Question: Marc Frahm - Cowen - Analyst : Okay. Thanks. That's helpful. And then new for Adam. Appreciate the cash guidance lessen in Q4. Can you remind us the current status of the covenants on new debt and just kind of where that is? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 12, 2022 / 12:30PM, XFOR.OQ - Q1 2022 X4 Pharmaceuticals Inc Earnings Call

Question: William Wood - B. Riley Securities - Analyst : Hi, good morning, everybody. This is William Wood on from Mayank Mamtani. Really appreciate you taking our calls and congratulations on all the advancements that you've made. A couple of questions from us. I was wondering if you could first, could you talk to how your view the WM landscape in light of the experience of our targeted therapies. And where you may think that the third quarter readout has an opportunity to improve perception as it relates to both safety and efficacy?

Question: William Wood - B. Riley Securities - Analyst : Yes, correct.

Question: William Wood - B. Riley Securities - Analyst : Thank you so much. Really appreciate that extra information there. Also, I mean, as you presented, you've got a number of clinical trials, providing data in the second half. I was just curious where we might be able to expect to see those data coming out throughout the year.

Question: Unidentified Participant - H.C. Wainwright - Analyst : Thank you. This is [Arkay] from HC Wainwright. Good morning, Paula and Adam. So I'm talking about the three buckets of patients under chronic neutropenia. Is the biology the same or similar among the three buckets? And you stated that you would have data among the three buckets. So assuming that the data is similar, is there a preference to go after one of them? Or what is the decision point there?

Question: Unidentified Participant - H.C. Wainwright - Analyst : Fantastic. Thank you very much for that. And then on the WHIM syndrome with the data coming out in fourth quarter. So, at the same time, you folks were identifying new mutations within the CXCR4. So when you present the data or when you start to analyze the data from fourth quarter onwards, are you going to go back and look at individual, individually you're going to be looking at the mutations just to understand how broad mavorixafor can be working on and do you think there will be any mutations where mavorixafor will not be able to interact with or not able to get the get the benefit, some of these patients, I'm just trying to understand how broad you can use mavorixafor in the WHIM syndrome.

Question: Unidentified Participant - H.C. Wainwright - Analyst : Fantastic. That's great. One last question. On the Waldenstrom indication when data comes out in the second half. What are the next steps in the sense?

Question: Unidentified Participant - H.C. Wainwright - Analyst : Okay. On Waldenstrom indication, what's the next step in the sense, once the data is presented in the second half? Would you be able to go straight into a registrational study? Or do you need to do an additional study before you go into registration?

Question: Trevor Howard - Oppenheimer - Analyst : Hi. Good morning. Just want to ask if you've had any conversations with Lilly or Merck, about a combination potential and expectations for how you might advance that combo. I also want to ask if you see any potential role for mav in activated PI3K Delta syndrome.

Question: Zegbeh Jallah - ROTH Capital - Analyst : Good morning, thanks for taking our questions. I just have three quick ones here. The first is about the Waldenstrom data. I know at that time of the last update, you had really strong responses in the relapsed refractory patients, but a little less in the frontline setting. So I was just wondering, with enrollment now complete, would you expect more patients or more relapsed refractory patients versus frontline patients. And then also regarding the 600 milligram dose that had started to be used. How should we think about the potential for that dose to kind of change the efficacy profile that we've seen for the program? And I have a couple follow up.

Question: Zegbeh Jallah - ROTH Capital - Analyst : Thanks, Diego. And then the follow up here is just about the WHIM program, you're on track to have your NDA submitter, which is a big deal. So looking at the way the stock is performing, wondering if you could just kind of again, highlight the commercial potential talk about some of the steps that you've taken, I know you have someone had in commercials so just kind of wondering if you can just kind of speak to that a little bit and then have the last one here as well.

Question: Zegbeh Jallah - ROTH Capital - Analyst : Thanks, Paula. And I don't know if you can say much about this. But this kind of said lays based on what you just ended with, regarding the broad commercial potential, I think you guys have had highlighted about 60,000 patients across the different diseases that you're looking at, you also